I-Acetylcholinesterase CAS:9000-81-1
Umphumela we-anticholinesterase ubhekisela emandleni emithi noma amakhemikhali athile okuvimbela umsebenzi we-enzyme i-acetylcholinesterase. I-Acetylcholinesterase inesibopho sokuphula i-neurotransmitter acetylcholine emzimbeni. Ngokuvimbela le enzyme, ama-anticholinesterase andisa amazinga e-acetylcholine, okuholela ekwandeni komsebenzi we-cholinergic.
Ukusetshenziswa okuyinhloko kwama-anticholinesterases kusekwelapheni izimo ezibonakala ngokuncipha komsebenzi we-cholinergic. Lokhu kufaka phakathi izifo zezinzwa ezifana nesifo se-Alzheimer kanye ne-myasthenia gravis. Esifweni se-Alzheimer, ama-anticholinesterase afana ne-donepezil, i-rivastigmine, kanye ne-galantamine asetshenziselwa ukuvimbela ukuwohloka kwe-acetylcholine nokuthuthukisa ukudluliswa kwe-cholinergic neurotransmission. Lokhu kungasiza ekuthuthukiseni ukusebenza kwengqondo futhi kunciphise ijubane lokuqhubeka kwesifo.
Ku-myasthenia gravis, ama-anticholinesterase afana ne-neostigmine kanye ne-pyridostigmine asetshenziswa ukuthuthukisa ukudluliselwa kwemisipha. Le mithi ivimbela i-acetylcholinesterase futhi inyuse amazinga e-acetylcholine endaweni yokuhlangana kwemisipha, ithuthukise amandla emisipha futhi inciphise ubuthakathaka bemisipha.
Ama-anticholinesterase nawo anezindlela zokuxilonga nokwelapha ezimweni zobuthi be-anticholinergic. Ama-anticholinergic compounds, njengezibulala-zinambuzane ezithile noma ama-nerve agents, angabangela ukuvinjelwa okukhulu kwe-cholinergic okuholela ezimpawini ezifana nokudideka, ukushaya kwenhliziyo okusheshayo, umlomo owomile, kanye nokungaboni kahle. Ezimweni ezinjalo, ama-anticholinesterase afana ne-pralidoxime angasetshenziswa ukuguqula imiphumela ngokwandisa amazinga e-acetylcholine nokuncintisana nezinto ezinobuthi.
| Ukwakheka | I-NA |
| Ukuhlolwa | 99% |
| Ukubukeka | Impuphu ephuzi ekhanyayo |
| Inombolo ye-CAS | 9000-81-1 |
| Ukupakisha | Encane futhi enkulu |
| Impilo Yeshelufu | iminyaka engu-2 |
| Isitoreji | Gcina endaweni epholile neyomile |
| Isitifiketi | I-ISO. |








